Viking Therapeutics price target lowered to $96 from $109 at B. Riley

14 hours ago · B. Riley lowered the firm’s price target on Viking Therapeutics to $96 from $109 and keeps a Buy rating on the shares. The firm remains a buyer on share weakness following the Q4 report.

CouponFollow Extension

$96
OFF

Viking Therapeutics Price Target Lowered To $96 From $109 At B. Riley

2 weeks from now

businessinsider.com

$90.00
OFF

Viking Therapeutics (NASDAQ:VKTX) Upgraded By B. Riley To …

2 weeks from now

Nov 23, 2024 · HC Wainwright lifted their price target on Viking Therapeutics from $90.00 to $102.00 and gave the company a "buy" rating in a research report on Monday, November 4th. …

marketbeat.com

$58.47
OFF

HC Wainwright Reiterates Buy Rating For Viking Therapeutics …

2 weeks from now

Dec 18, 2024 · The business has a 50 day moving average price of $58.47 and a 200 day moving average price of $58.06. Viking Therapeutics has a fifty-two week low of $17.23 and a fifty-two …

marketbeat.com

$109.00
OFF

B.Riley Financial Reaffirms Their Buy Rating On Viking Therapeutics ...

2 weeks from now

Dec 20, 2024 · B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $109.00. The …

businessinsider.com

$1.06
OFF

Viking Therapeutics (NASDAQ:VKTX) Earns "Buy" Rating From

2 weeks from now

Jan 8, 2025 · Viking Therapeutics Trading Down 2.5 %. Shares of Viking Therapeutics stock traded down $1.06 during trading hours on Wednesday, reaching $40.60. 2,038,876 shares of …

marketbeat.com

$109
OFF

Viking Therapeutics Initiated With A Buy At B. Riley

2 weeks from now

Nov 22, 2024 · B. Riley analyst Mayank Mamtani initiated coverage of Viking Therapeutics with a Buy rating and $109 price target The firm has confidence in the “long-term disruptive potential” …

businessinsider.com

27%
OFF

After Crashing 27% In The Past Month, Is Viking Therapeutics Stock …

2 weeks from now

Dec 3, 2024 · And one of them is Viking Therapeutics (VKTX-2.59%), which has a promising GLP-1 treatment in development that investors are hopeful will generate billions in revenue for …

fool.com

8%
OFF

Viking Therapeutics (NASDAQ:VKTX) Shares Up 1.8% - Still A Buy?

2 weeks from now

Dec 9, 2024 · Morgan Stanley reiterated an "overweight" rating and issued a $105.00 target price on shares of Viking Therapeutics in a research note on Thursday, September 12th. B. Riley …

marketbeat.com

$90.00
OFF

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average

2 weeks from now

Nov 18, 2024 · HC Wainwright upped their price objective on Viking Therapeutics from $90.00 to $102.00 and gave the stock a "buy" rating in a report on Monday, November 4th. Finally, …

marketbeat.com

$102.00
OFF

Viking Therapeutics’ Promising Phase 2 Trial And Competitive Edge ...

2 weeks from now

Jan 8, 2025 · H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $102.00. Discover …

businessinsider.com

8%
OFF

Viking Therapeutics (NASDAQ:VKTX) Trading 4.8% Higher

2 weeks from now

Dec 20, 2024 · Morgan Stanley reaffirmed an "overweight" rating and issued a $105.00 target price on shares of Viking Therapeutics in a research report on Thursday, September 12th. …

marketbeat.com

FAQs about Viking Therapeutics price target lowered to $96 from $109 at B. Riley Coupon?

When will Viking Therapeutics vktx report earnings?

Viking Therapeutics VKTX is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for earnings is pegged at a loss of 27 cents per share. ...

Is Viking Therapeutics a good buy?

Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Trevi Therapeutics, and Altimmune. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $111.40 average price target, which is a 152.15% upside from current levels. ...

Should you buy Viking Therapeutics (vk2735)?

B. Riley analyst Mayank Mamtani initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $109 price target The firm has confidence in the “long-term disruptive potential” of the company’s lead program VK2735 in the “fast-expanding” obesity and type 2 diabetes metabolic dysfunction-associated steatohepatitis landscape. ...

Is Viking Therapeutics stock still up 80% this year?

Although it looks like there may be some mounting pessimism surrounding Viking Therapeutics stock recently, its shares are still up more than 180% this year, as of the end of last week. Investors may simply be cashing out some profits heading into the close of 2024. ...

Where is Viking Therapeutics (vktx) headquartered?

The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA. View Viking Therapeutics, Inc. VKTX stock quote prices, financial information, real-time forecasts, and company news from CNN. ...

Will Viking Therapeutics (vktx) lead to an acquisition?

And one of them is Viking Therapeutics (VKTX -2.54%), which has a promising GLP-1 treatment in development that investors are hopeful will generate billions in revenue for the modestly sized healthcare company. It may even lead to an acquisition. In the past month, however, excitement around Viking has cooled, considerably. ...